AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 157 filers reported holding AKERO THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,698 | -33.9% | 33,582 | -38.9% | 0.00% | -50.0% |
| Q2 2023 | $2,567 | +782.1% | 55,001 | +622.4% | 0.00% | – |
| Q1 2023 | $291 | -79.8% | 7,614 | -71.0% | 0.00% | -100.0% |
| Q4 2022 | $1,440 | -99.9% | 26,286 | -66.5% | 0.00% | -33.3% |
| Q3 2022 | $2,668,000 | – | 78,371 | +75988.3% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 103 | -39.8% | 0.00% | – |
| Q1 2022 | $2,000 | -99.3% | 171 | -98.5% | 0.00% | – |
| Q3 2021 | $295,000 | -2.0% | 11,642 | -4.1% | 0.00% | – |
| Q2 2021 | $301,000 | -84.8% | 12,142 | -82.2% | 0.00% | -100.0% |
| Q1 2021 | $1,974,000 | – | 68,063 | +340215.0% | 0.00% | – |
| Q2 2020 | $0 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |